Home healthcare provider Addus HomeCare (NASDAQ: ADUS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 21.8% year on year to $349.4 million. Its non-GAAP profit of $1.49 per share was 1.8% above analysts’ consensus estimates.
Is now the time to buy ADUS? Find out in our full research report (it’s free).
Addus HomeCare (ADUS) Q2 CY2025 Highlights:
- Revenue: $349.4 million vs analyst estimates of $346.5 million (21.8% year-on-year growth, 0.8% beat)
- Adjusted EPS: $1.49 vs analyst estimates of $1.46 (1.8% beat)
- Adjusted EBITDA: $43.93 million vs analyst estimates of $43.08 million (12.6% margin, 2% beat)
- Operating Margin: 9.4%, in line with the same quarter last year
- Sales Volumes rose 32.7% year on year (-2.8% in the same quarter last year)
- Market Capitalization: $2.05 billion
StockStory’s Take
Addus HomeCare’s second quarter saw a significant positive reaction from the market, driven by outperformance on both revenue and adjusted profit compared to Wall Street expectations. Management attributed the strong results to continued momentum in personal care hiring, robust execution in the recently acquired Gentiva operations, and favorable reimbursement trends in large states such as Illinois and Texas. CEO Dirk Allison emphasized that personal care volume growth and strategic acquisitions like Gentiva and Helping Hands were key contributors, stating, “We are confident that personal care services continue to deliver real value to state Medicaid programs as well as our managed care partners.”
Looking ahead, Addus HomeCare’s management believes revenue growth will be supported by recently legislated reimbursement rate increases in Illinois and Texas and ongoing expansion through targeted acquisitions. CFO Brian Poff noted, “We expect to benefit from additional rate increases in Illinois and Texas,” while COO Brad Bickham highlighted further rollout of digital caregiver tools and the potential for additional state-level rate improvements. However, management also acknowledged ongoing challenges in clinical hiring and the risk of future federal payment reductions in home health, with Allison cautioning that “the proposed home health rule will most likely continue to delay any meaningful home health opportunities.”
Key Insights from Management’s Remarks
Management identified strong personal care growth, state reimbursement increases, and successful integration of recent acquisitions as primary drivers of the quarter’s results.
- Personal Care Hiring Momentum: Management credited improved hiring trends in the Personal Care segment as a central driver, with new hiring systems and digital caregiver tools increasing fill rates and supporting growth in hours served, particularly in major markets like Illinois.
- State Reimbursement Rate Increases: Recently finalized state budgets in Illinois and Texas included reimbursement rate hikes for personal care services, which Addus expects will add over $35 million in annualized revenue starting later this year and into 2026, at margins consistent with current operations.
- Acquisition Integration: The second full quarter of Gentiva Personal Care operations and the newly acquired Helping Hands Home Care in Pennsylvania expanded Addus’ service footprint, enhancing both personal care and clinical capabilities in targeted regions.
- Segment Performance Divergence: While the Personal Care and Hospice segments posted strong organic growth, the Home Health segment continued to face revenue declines despite operational improvements, with management citing ongoing payer negotiations and the impact of proposed Medicare payment reductions on acquisition activity.
- Technology Rollout and Retention: The caregiver application, now adopted by 90% of Illinois caregivers and expanding to other states, is designed to improve fill rates and potentially enhance caregiver retention by offering greater schedule flexibility and visibility.
Drivers of Future Performance
Addus expects reimbursement rate increases, ongoing acquisitions, and operational enhancements to underpin revenue and margin stability, but faces headwinds from regulatory uncertainty and labor constraints.
- State Rate Increases Fuel Growth: Management anticipates that recently approved reimbursement rate increases in Illinois and Texas will drive additional revenue, with both expected to contribute at comparable margins to existing business lines. These changes should support further organic growth, particularly in personal care services.
- Acquisition Strategy Remains Active: Addus plans to continue pursuing smaller, targeted acquisitions to expand density in existing markets and add clinical capabilities. The company believes this approach will help offset challenges in larger-scale home health acquisitions due to ongoing regulatory uncertainty around Medicare payment rules.
- Labor Market and Regulatory Risks: While personal care hiring remains robust, management noted that clinical hiring, particularly for nurses, will remain challenging and may limit growth in clinical services. Additionally, the proposed 6.4% reduction in Medicare payments for home health agencies in 2026 introduces risk for both organic and inorganic growth in that segment.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) the implementation and impact of state reimbursement increases in Illinois and Texas, (2) continued expansion through acquisitions like Helping Hands and integration of clinical services, and (3) progress with digital caregiver tools in additional markets. We will also track regulatory developments around Medicare payment rules, which remain a significant variable for home health segment performance.
Addus HomeCare currently trades at $113.25, up from $107.13 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.